Tokyo, Feb. 27 (Jiji Press)–Asahi Kasei Corp. has said it will acquire German pharmaceutical developer Aicuris Anti-Infective Cures AG for some 780 million euros. The major Japanese chemical maker will obtain all outstanding Aicuris shares through a U.S. subsidiary, planning to complete the acquisition in April-June. Asahi Kasei aims to expand profits in the medical field, a growth area for the company. Aicuris, which has strengths in antiviral drugs, earned 132 million euros in sales in 2025. The German company “exactly matches our need,” Asahi Kasei President Koshiro Kudo said at a press conference held in Tokyo on Thursday to announce the deal. Asahi Kasei is shifting its focus to pharmaceutical and electronic material operations as its petrochemical business has been sluggish. With the planned acquisition, the firm is seeking to achieve its goal of generating sales of 300 billion yen at the pharmaceutical division in fiscal 2030. END [Copyright The Jiji Press, Ltd.]
Asahi Kasei to Acquire German Drug Developer Aicuris
Related Posts
Japan’s Industrial Output Rises 2.2 Pct in Jan.
Tokyo, Feb. 27 (Jiji Press)–Japan’s industrial production in January rose 2.2 pct from the previous month, mainly due to robust output of automobile-related products, the industry ministry said Friday. The seasonally adjusted production index for the manufacturing and mining sectors stood at
Japan Team Creates Mouse Testicular Organoids in Vitro
Tokyo, Feb. 27 (Jiji Press)–A Japanese team of researchers has developed miniaturized testicular tissues known as testicular organoids from mouse embryonic stem cells in an experimental vessel, marking a world first. The achievement by the team, comprising University of Osaka professor Katsuhiko
